Cervical cancer is a significant cause of morbidity and mortality among women worldwide. Radiotherapy, in combination with chemotherapy or as a standalone treatment, is an effective treatment option for cervical cancer. However, traditional radiotherapy has its limitations, such as the potential for damage to surrounding healthy tissues. Stereotactic Body RadioTherapy (SBRT) is a newer radiotherapy technique that delivers high doses of radiation to the tumor with minimal damage to the surrounding tissues. This study aims to evaluate the safety of Stereotactic Body RadioTherapy to involved node in cervical cancer.
Patients with stage IIIC cervical cancer
No previous pelvic radiation therapy or surgery
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Patients with stage I or stage II or stage IV disease.
Patients with prior malignancies or active autoimmune diseases
Uncontrolled medical comorbidity